Novartis quietly drops three pipeline projects

Novartis has terminated development of three mid- to late-stage pipeline projects, Scrip discovered after comparing the company's 1Q 2014 and 4Q 2013 results. The dropped products include secukinumab in its uveitis indication, a Phase IIb/III product to treat fragile X syndrome, and a Phase II drug to treat Clostridium difficile infection.